These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 16849420

  • 1. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [Abstract] [Full Text] [Related]

  • 2. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
    Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4845-52. PubMed ID: 17848408
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 4. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 5. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
    Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R.
    J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
    [Abstract] [Full Text] [Related]

  • 6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 7. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 8. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.
    Proc Natl Acad Sci U S A; 2002 Oct 29; 99(22):14374-9. PubMed ID: 12391322
    [Abstract] [Full Text] [Related]

  • 9. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
    Wunderlich A, Arndt T, Fischer M, Roth S, Ramaswamy A, Greene BH, Brendel C, Hinterseher U, Bartsch DK, Hoffmann S.
    J Surg Oncol; 2012 Mar 15; 105(4):357-64. PubMed ID: 22006286
    [Abstract] [Full Text] [Related]

  • 10. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.
    Clin Cancer Res; 2009 Dec 01; 15(23):7153-60. PubMed ID: 19934289
    [Abstract] [Full Text] [Related]

  • 11. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 01; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.
    Int J Urol; 2012 Jun 01; 19(6):565-74. PubMed ID: 22324515
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS.
    Cancer Res; 2001 May 01; 61(9):3535-40. PubMed ID: 11325813
    [Abstract] [Full Text] [Related]

  • 15. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 16. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y, Rahmani M, Grant S.
    Oncogene; 2003 Oct 16; 22(46):7108-22. PubMed ID: 14562039
    [Abstract] [Full Text] [Related]

  • 17. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M, Zhang PL, Pellitteri PK, Law A, Kennedy TL, Brown RE.
    Ann Clin Lab Sci; 2005 Oct 16; 35(3):251-8. PubMed ID: 16081580
    [Abstract] [Full Text] [Related]

  • 18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr 16; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 19. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS.
    Oncol Rep; 2008 Apr 16; 19(4):1027-32. PubMed ID: 18357392
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.